SFDA-2023-0017-V317

Type II variation for application SFDA-2023-0017. Type II variation: Facility Change for Thymosilib — major revision

Variation Number
SFDA-2023-0017-V317
Type
Type II
Application
SFDA-2023-0017
Change
CHG-2024-0017
Status
Draft
Fee
€38,301
Submitted
2023-01-01
Approved
—
Description

Type II variation: Facility Change for Thymosilib — major revision